Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Interventional × Trimetazidine × Clear all

Phase

Phase 2/3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Cardiotoxicity 1

Interventions

Cisplatin 77 Fluorouracil 53 Gemcitabine 52 Docetaxel 51 Paclitaxel 50 Oxaliplatin 49 Cyclophosphamide 47 Carboplatin 47 Capecitabine 47 Drug Therapy 42 Radiotherapy 40 pembrolizumab 33 Leucovorin 30 Bevacizumab 30 Doxorubicin 26 Dexamethasone 25 Magnetic Resonance Spectroscopy 23 Cytarabine 23 Etoposide 22 Nivolumab 21 Pemetrexed 20 Methotrexate 20 Radiation 16 apatinib 15 Prednisone 15 venetoclax 14 Vincristine 14 Temozolomide 14 Rituximab 14 Irinotecan 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04939857 2021-06-25

Effect of Trimetazidine on Radiotherapy-induced Heart Damage.

Peking University Third Hospital

Phase 2/3 Unknown

Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon ⚡